Assistant Professor, Departments of Pathology and Medicine
Ben May Department for Cancer Research
Committee on Cancer Biology
Committee on Immunology
The Cancer Research Center
B.A. University of Chicago (Biology)
M.D. University of Chicago Pritzker School of Medicine
Ph.D. University of Chicago (Immunology)
CIS W436
Voice: 773/ 702.4601
Fax: 773/ 702.3701
Thomas Gajewski, M.D., Ph.D.
Research / References
Fields, P., Gajewski, T.F., and Fitch, F.W. Blocked Ras activation in anergic CD4+ T cells. Science. 271:1276-1278. 1996.
Fallarino, F., Uyttenhove, C., Boon, T., and Gajewski, T.F. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol. 156:1095-1100. 1996.
Bird, J.J., Brown, D.R., Mullen, A.C., Moskowitz, N.H., Gajewski, T.F., Wang, C.-R., and Reiner, S.L. Helper T cell differentiation is controlled by the cell cycle. Immunity. 9:229-237. 1998.
Wan, Y.Y., Leon, R.P., Marks, R., Cham, C.M., Schaack, J., Gajewski, T.F., and DeGregori, J. Transgenic expression of the coxsackie/adenovirus receptor (CAR) enables adenoviral mediated gene delivery in naive T cells. Proc.Natl.Acad.Sci.USA. In Press. 2000.
Fallarino, F., Uyttenhove, C., Boon, T., and Gajewski, T.F. Improved efficacy of dendritic cell vaccines, and successful immunization with tumor antigen peptide-pulsed PBMC, by co-administration of rmIL-12. Int. J. Cancer. 80:324-333. 1999.
Kacha, A.K., Fallarino, F., Markiewicz, M.A., and Gajewski, T.F. Cutting Edge: Spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J.Immunol. In Press. 2000
Gajewski, T.F., Fallarino, F., Ashikari, A. and Sherman, M.L. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous PBMC plus rhIL-12. Clin. Cancer Res. In Press. 2000.